TRENDS IN THE DOMESTIC MARKET OF NON–VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS: AN ANALYTICAL REVIEW
DOI:
https://doi.org/10.11603/2312-0967.2025.2.15437Keywords:
medication, pharmaceutical market, non–vitamin K antagonist oral anticoagulants, assortment, availability, Defined Daily Dose, consumption volumeAbstract
The aim of the work was to investigate the range of registered non–vitamin K antagonist oral anticoagulants (NOACs) and their physical availability in Ukrainian pharmacies, as well as to analyse the retail market of NOACs for the period 2020-2024.
Materials and Methods. An analysis was conducted on data from the State Register of Medicines of Ukraine, information on the physical availability of medicines in pharmacies, and data on the sales volumes of oral anticoagulants and NOACs. A range of analytical and synthetic approaches, including comparison, generalization, content analysis, mathematical-statistical, and graphical methods, were employed.
Results and Discussion. As of December 2024, it was found that four NOAC INNs (dabigatran etexilate, rivaroxaban, apixaban and edoxaban) were registered in Ukraine under six trade names and 20 assortment positions, predominantly in tablet form. Bayer AG (Germany) and Pharmadox Healthcare Limited (Malta) are the leaders in terms of production activity index (PAI) among companies, while Germany leads among countries. Heterogeneity in the physical availability of individual NOAC trade names and dosages in pharmacies was identified. The oral anticoagulant market in Ukraine fluctuated during 2020–2024, with the pharmacy segment consistently dominating and occupying over 98% of the market. The consumption of NOACs has increased significantly, with a notable rise in their share of total oral anticoagulant consumption. In the pharmacy sector, the percentage of NOACs rose from 53.73% in 2020 to 78.83% in 2024, while in the hospital sector, it increased from 6.78% in 2020 to 68.18% in 2024. A rapid increase in the share of domestically produced NOACs was noted, reaching approximately 24% of the NOAC market in 2024. Against a backdrop of a gradual decline in sales volumes of traditional anticoagulants such as warfarin and phenindione, a steady increase in the popularity of NOACs, primarily rivaroxaban and edoxaban, was observed.
Conclusions. It has been demonstrated that the NOAC market in Ukraine has exhibited vigorous development and growth during the period 2020–2024, thereby displacing traditional anticoagulants. Key trends identified include the predominance of rivaroxaban, an increase in the share of domestically produced drugs, and the marked predominance of NOACs in the pharmacy retail segment of the market.
References
Paliienko IA, Karpenko OV. Zastosuvannia priamykh oralnykh antykoahuliantiv pry zakhvoriuvanniakh nyrok [Use of direct oral anticoagulants in kidney diseases]. Kidneys. 2025;14(1):77-90. DOI: 10.22141/2307-1257.14.1.2025.507. Ukrainian. DOI: https://doi.org/10.22141/2307-1257.14.1.2025.507
Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;42(5):373-498. DOI: 10.1093/eurheartj/ehaa612. DOI: https://doi.org/10.1093/eurheartj/ehaa945
January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC Jr, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. Circulation. 2019;140(2). DOI: 10.1161/CIR.0000000000000665. DOI: https://doi.org/10.1161/CIR.0000000000000665
Steffel J, Collins R, Antz M, Cornu P, Desteghe L, Haeusler KG, et al. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace. 2021;23(10):1612-76. DOI: 10.1093/europace/euab065. DOI: https://doi.org/10.1093/europace/euab157
Henyk P, Levytska O, Chukhrai I, Yarko N, Tereshchuk S, Hromovyk B. Protyepileptychni likarski zasoby yak obiekty natsionalnoho farmatsevtychnoho rynku. Povidomlennia 1. Kharakterystyka nomenklatury protyepileptychnykh likarskykh zasobiv z pohliadu prohramy derzhavnykh harantii medychnoho obsluhovuvannia naselennia [Antiepileptic drugs as objects of the national pharmaceutical market. Communication 1. Characteristics of the nomenclature of antiepileptic drugs from the perspective of the state guarantees program for medical care of the population]. Analy Mechnykovskoho Instytutu. 2023;(4):90-8. DOI: 10.5281/zenodo.10256357.
WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment 2024. Oslo: WHO Collaborating Centre for Drug Statistics Methodology; 2024. Available from: https://atcddd.fhi.no/ddd/definition_and_general_considera/
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Pharmaceutical Review / Farmacevtičnij časopis
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The authors who publish their materials in this journal agree with the following terms:
- Authors reserve the right to authorship of their work and assign to the journal the right to first publish this work under the terms of the Creative Commons Attribution License, which allows other persons to freely distribute the published work with a mandatory reference to the authors of original work and the first publication of work in this journal
. - Authors have the right to make independent extra-exclusive work agreements in the form they are published by this journal (for example, posting work in an electronic repository of an institution or publishing as part of a monograph), provided that the link to the first publication of the work in this journal is maintained.
Journal policy allows and encourages publication of manuscripts on the Internet (for example, in institutions repositories or on personal websites), both before the publication of this manuscript and during its editorial review, as it contributes to productive scientific discussion and positively affects the efficiency and dynamics of the citation of the published work (see The Effect of Open Access).
